Where’s The Bolus? ANDA Projections For FY 2015 Don’t Reflect Past, Future Surges
This article was originally published in The Pink Sheet Daily
Generic drug makers will face higher facility fees but lower application fees next fiscal year.
You may also be interested in...
User fee revenue expected to break $1bn threshold by FY 2020, but growth looks to be slower than last few years.
US FDA’s expedited pathway remains alive and well in oncology, but ‘dangling’ indications may be subject to more regular public scrutiny going forward; negative votes for two of six indications reflected the influence of Oncology Center of Excellence director Richard Pazdur.
Measure clarifies the meaning of new chemical entity by replacing the term ‘active ingredient,’ which encompasses esters and salts, with ‘active moiety’ as defined by the FDA; legal experts are skeptical the measure will generate cost savings and say it gives the agency wide latitude to make future changes in eligibility for 5-year exclusivity.